PharmaLegacy will be attending Bio-Europe Spring, March 18-20 in Barcelona Spain. Let’s connect there to discuss the latest trends and challenges in the pharma industry.
You can register here for Bio-Europe Spring, and email michael.zhang@pharmalegacy.com to schedule a meeting.
We hope to see you in Barcelona!
PharmaLegacy will be exhibiting at the 2024 meeting of the American Association for Cancer Research April 7 – 10 in California. Visit us at booth #4428 and let’s discuss how our latest oncology and immuno-oncology in vitro and in vivo models can help you predict outcomes for potential treatments.
You can register here for AACR 2024
We hope to see you in California!
PharmaLegacy will be exhibiting at the 2024 Society Of Toxicology’s 63rd annual meeting and ToxExpo March 11– 13 in Salt Lake City. Visit us at booth #940 and let’s discuss how our fast, cost-effective toxicology services can bolster your studies.
To register at ToxExpo 2024, visit https://www.toxicology.org/events/am/AM2024/registration.asp#:~:text=Exhibitor%20Registration,3115).
We hope to see you in Salt Lake City!
Recently, The Lancet published the world’s first clinical trial study on gene therapy for hereditary deafness. This study has proved the safety and demonstrated the great potential of gene therapy for the treatment of hereditary deafness, which has attracted extensive attention from medical community.
The deafness gene therapy drug RRG-003 (AAV1-hOTOF), used in this study was jointly developed by Eye & ENT Hospital of Fudan University, Harvard Medical School and Shanghai Refreshgene Therapeutics Co., Ltd. This study reported the safety and efficacy of gene therapy with an adeno-associated virus (AAV) serotype 1 carrying a human OTOF transgene (AAV1-hOTOF) as a treatment for children with autosomal recessive deafness 9.
Preclinical studies of this gene therapy were published in November 2023 in Molecular Therapy-Methods & Clinical Development. PharmaLegacy participated in the preclinical safety evaluation of the gene therapy, helping it to smoothly start the IIT study.
PharmaLegacy’s advanced and comprehensive hearing research platform can provide services ranging from early product development to preclinical research, including pharmacokinetic, efficacy, and safety evaluation. The team has extensive experience helping clients all over the globe in their preclinical stage R&D.
A variety of hearing impairment models can be provided by PharmaLegacy, including noise exposure, chemotherapy drug induction (e.g. cisplatin), aminoglycoside antibiotic induction, transgenic mice, aged mice, and others.
PharmaLegacy’s hearing team has rich experience in local delivery, and accurately completed the injection without affecting hearing.
Middle ear delivery (1. Transtympanic injection; 2. Bulla ostomy)
Inner ear delivery (3. Round window membrane delivery; 4. Posterior semicircular canal injection; 5. Cochlea ostomy)
PharmaLegacy provides drug PK laboratory services, including local PK (Perilymph collection).
PharmaLegacy has multiple sets of hearing test system that provide high-throughput auditory brainstem response, ABR) and distortion product otoacoustic emissions (DPOAES).
PharmaLegacy provides isolation, culture, and drug evaluation in newborn animals of cochlear explants and spiral ganglion neurons (SGNs).
PharmaLegacy conducts hearing studies in mice, rats, guinea pigs, and non-human primates.
A variety of ex vivo assay services are available, including cochlear implants, frozen/paraffin sections, immunofluorescence and immunohistochemistry.
PharmaLegacy’s confocal imaging platform (Nikon AX laser confocal microscope) can fully meet various requirements for high-quality imaging.
PharmaLegacy will be exhibiting at the 2023 meeting of the Association for Research in Vision & Ophthalmology April 23 – 27 in New Orleans. Visit us at booth #1449 and discuss predicting outcomes for potential treatments with our latest ophthalmology models.
To register at ARVO 2023, visit https://23annual.com/arvo/index.php
We hope to see you in New Orleans!
PharmaLegacy will be exhibiting at the 2023 meeting of the American Association for Cancer Research April 14 – 18 in Florida. Visit us at booth #71 and discuss predicting outcomes for potential treatments with our latest oncology and immuno-oncology in vitro and in vivo models.
To register for AACR 2022, visit https://www.annualconference2023.com/aacr/?gclid=Cj0KCQjwwtWgBhDhARIsAEMcxeAk0-cT_qLX_fVmdTHKvgmbeSE-n_qFBu9Gpl7yB2bjd1tnvdZU4N8aAgFHEALw_wcB
We hope to see you in Florida!
